Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04374630 · ClinicalTrials.gov registry record · Phase 2
Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian
A Phase 2 study, sponsored by Laekna Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT04374630: Completed Phase 2 study, sponsored by Laekna Limited.
NCT04374630 is a Phase 2 study that has completed, run by Laekna Limited. The registered enrollment target is 150 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (13% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04374630, a Phase 2 study, has completed, sponsored by Laekna Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
Afuresertib is an AKT inhibitor, a new class of agents under development that may provide physicians with a new clinical option to control platinum resistant ovarian cancer (PROC) progression. Afuresertib plus chemotherapy has demonstrated anti-tumor efficacy and an acceptable safety profile in patients with PROC in a published Phase I/II study. Therefore, the combination of afuresertib plus weekly paclitaxel could represent a clinically meaningful step forward in the clinical management of these difficult-to-treat patients with PROC.
Primary Outcome
Radiographic imaging will be performed and assessed by investigators
Interventions
- DRUG Paclitaxel
- DRUG Afuresertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2020-06-09 |
| Est. Completion | 2024-06-28 |
| Phase | Phase 2 |
What the finished NCT04374630 record still lists
NCT04374630 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (13% higher).
The record links to 0 conditions, and to 2 interventions - of which Paclitaxel is the first listed.
NCT04374630 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04374630 about?
NCT04374630 is a clinical study titled "Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian". Afuresertib is an AKT inhibitor, a new class of agents under development that may provide physicians with a new clinical option to control platinum resistant ovarian cancer (PROC) progression. Afuresertib plus chemotherapy has demonstrated anti-tumor efficacy and an acceptable safety profile in pati...
What is the current status of trial NCT04374630?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2020-06-09. Estimated completion is 2024-06-28.
What interventions are being tested in trial NCT04374630?
The interventions under investigation include: Paclitaxel (DRUG), Afuresertib (DRUG).
Who is sponsoring clinical trial NCT04374630?
This trial is sponsored by Laekna Limited, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04374630's enrollment target sits among peer trials
150 455th of 2000 higher than 1,510 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI